Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Over the last decade it has become increasingly clear that eye disorders are amongst the most amenable targets for gene therapy. This issue surveys ocular gene transfer using AAV and lentiviral vectors which are the most effective vector platforms for the eye and also surveys gene therapy approaches for the treatment of a range of retinal disorders, including inherited retinopathies, glaucoma and retinal and choroidal neovascularisation.
Guest Editor Robin R Ali, University College London, United Kingdom